BioCentury | Aug 7, 2015
Financial News

Cold Genesys raises $10M in series B

...in combination with immune checkpoint modulators. Cold Genesys licensed rights to CG0070 in 2010 from BioSante Pharmaceuticals Inc....
BioCentury | May 21, 2015
Product R&D

Aduro's STING

...compound. GVAX is a GM-CSF-based cancer vaccine which Aduro acquired from BioSante Pharmaceuticals Inc. in 2013 before BioSante...
BioCentury | Jul 28, 2014
Clinical News

CRS-207 regulatory update

...mesothelin . In February 2013, Aduro acquired all assets related to GVAX cancer vaccines from BioSante Pharmaceuticals Inc....
...vaccines to treat pancreatic and prostate cancer (see BioCentury, Feb. 11, 2013). In June 2013, BioSante...
BioCentury | Jul 28, 2014
Clinical News

GVAX Pancreas cancer vaccine regulatory update

...mesothelin . In February 2013, Aduro acquired all assets related to GVAX cancer vaccines from BioSante Pharmaceuticals Inc....
...vaccines to treat pancreatic and prostate cancer (see BioCentury, Feb. 11, 2013). In June 2013, BioSante...
BioCentury | Jul 14, 2014
Company News

RestorGenex Corp management update

...Dermatology, Ophthalmic Hired: Phillip Donenberg as CFO, formerly SVP of finance, CFO and secretary of BioSante Pharmaceuticals Inc....
BioCentury | Mar 24, 2014
Company News

Meda, Mission Pharmacal sales and marketing update

...which had a sub-license to the product from ANI Pharmaceuticals (NASDAQ:ANIP, Baudette, Minn.)(formerly BioSante Pharmaceuticals Inc. ). BioSante...
BioCentury | Mar 17, 2014
Company News

RestorGenex management update

...Calif. Business: Dermatology, Ophthalmic Hired: Stephen Simes as CEO, formerly president, CEO and vicechairman of BioSante Pharmaceuticals Inc....
BioCentury | Feb 17, 2014
Clinical News

GVAX Pancreas cancer vaccine: Phase IIb started

...13 and 16. Last year, Aduro acquired all assets related to GVAX cancer vaccines from BioSante Pharmaceuticals Inc....
...GVAX vaccines to treat pancreatic and prostate cancer (see BioCentury, Feb. 11, 2013). In June, BioSante...
BioCentury | Feb 17, 2014
Clinical News

CRS-207: Phase IIb started

...13 and 16. Last year, Aduro acquired all assets related to GVAX cancer vaccines from BioSante Pharmaceuticals Inc....
...GVAX vaccines to treat pancreatic and prostate cancer (see BioCentury, Feb. 11, 2013). In June, BioSante...
BioCentury | Feb 10, 2014
Clinical News

CRS-207: Updated Phase II data

...treat pancreatic cancer. Last year, Aduro acquired all assets related to GVAX cancer vaccines from BioSante Pharmaceuticals Inc....
...GVAX vaccines to treat pancreatic and prostate cancer (see BioCentury, Feb. 11, 2013). Last June, BioSante...
Items per page:
1 - 10 of 249
BioCentury | Aug 7, 2015
Financial News

Cold Genesys raises $10M in series B

...in combination with immune checkpoint modulators. Cold Genesys licensed rights to CG0070 in 2010 from BioSante Pharmaceuticals Inc....
BioCentury | May 21, 2015
Product R&D

Aduro's STING

...compound. GVAX is a GM-CSF-based cancer vaccine which Aduro acquired from BioSante Pharmaceuticals Inc. in 2013 before BioSante...
BioCentury | Jul 28, 2014
Clinical News

CRS-207 regulatory update

...mesothelin . In February 2013, Aduro acquired all assets related to GVAX cancer vaccines from BioSante Pharmaceuticals Inc....
...vaccines to treat pancreatic and prostate cancer (see BioCentury, Feb. 11, 2013). In June 2013, BioSante...
BioCentury | Jul 28, 2014
Clinical News

GVAX Pancreas cancer vaccine regulatory update

...mesothelin . In February 2013, Aduro acquired all assets related to GVAX cancer vaccines from BioSante Pharmaceuticals Inc....
...vaccines to treat pancreatic and prostate cancer (see BioCentury, Feb. 11, 2013). In June 2013, BioSante...
BioCentury | Jul 14, 2014
Company News

RestorGenex Corp management update

...Dermatology, Ophthalmic Hired: Phillip Donenberg as CFO, formerly SVP of finance, CFO and secretary of BioSante Pharmaceuticals Inc....
BioCentury | Mar 24, 2014
Company News

Meda, Mission Pharmacal sales and marketing update

...which had a sub-license to the product from ANI Pharmaceuticals (NASDAQ:ANIP, Baudette, Minn.)(formerly BioSante Pharmaceuticals Inc. ). BioSante...
BioCentury | Mar 17, 2014
Company News

RestorGenex management update

...Calif. Business: Dermatology, Ophthalmic Hired: Stephen Simes as CEO, formerly president, CEO and vicechairman of BioSante Pharmaceuticals Inc....
BioCentury | Feb 17, 2014
Clinical News

GVAX Pancreas cancer vaccine: Phase IIb started

...13 and 16. Last year, Aduro acquired all assets related to GVAX cancer vaccines from BioSante Pharmaceuticals Inc....
...GVAX vaccines to treat pancreatic and prostate cancer (see BioCentury, Feb. 11, 2013). In June, BioSante...
BioCentury | Feb 17, 2014
Clinical News

CRS-207: Phase IIb started

...13 and 16. Last year, Aduro acquired all assets related to GVAX cancer vaccines from BioSante Pharmaceuticals Inc....
...GVAX vaccines to treat pancreatic and prostate cancer (see BioCentury, Feb. 11, 2013). In June, BioSante...
BioCentury | Feb 10, 2014
Clinical News

CRS-207: Updated Phase II data

...treat pancreatic cancer. Last year, Aduro acquired all assets related to GVAX cancer vaccines from BioSante Pharmaceuticals Inc....
...GVAX vaccines to treat pancreatic and prostate cancer (see BioCentury, Feb. 11, 2013). Last June, BioSante...
Items per page:
1 - 10 of 249